Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

NeuroEM Therapeutics is poised to deliver a knockout blow to Alzheimer’s disease. The clinical-stage medical device company is pleased to announce FDA Breakthrough Device designation for its bioengineered head device shown to reverse Alzheimer’s memory loss in its pilot study, published last fall in the Journal of Alzheimer’s Disease.

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.

Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.

Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first large-scale, pivotal clinical trial.

As part of a strategic reorganization intended in part to support the ongoing launch of its postpartum depression drug, Sage Therapeutics is cutting more than 165 employees.

NeuroEM Therapeutics, a clinical stage medical device company focused on neurodegenerative diseases, today announced findings from an early stage study, which assessed safety and initial efficacy of transcranial electromagnetic treatment (TEMT) with the company’s investigational MemorEM™ head device for Alzheimer’s disease (AD)